SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SCIO Scios Inc.
SCIO 0.010000.0%Aug 19 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ubrx who wrote (960)12/30/1998 1:38:00 PM
From: Miljenko Zuanic  Read Replies (1) of 1477
 
Anti-angiogenesis:

Cancernet has anti-angiogenesis web page:
207.121.187.155

and from CELG SI tread:
Message 6655806

For angio-factors and neovascularization search medline for FGF, VEGF and Ang-1 (three most powerful vascular growth factors).

I will not agree with this statement:

<<There are certainly several different angiogenic growth factors in research. Scios is a player in this field with two major entries,
bFGF and VEGF121, but is seems that others are further advanced with the research at this point. >>

SCIO was first to run PIII pivotal trial with angio-factor, and completed three PII trials. Competitors Chiron and Genentech are at PII phase with bFGF and VEGF.

One can run hundreds experiments and preclinical studies, but what count is when you put drug in humans. When you administrated drug to sick people, not animals or healthy volunteers. Now SCIO/AHP have over 800 pts to study drug performance and effects. If drug formulation is OK clinical data can be significant advantage in future.

I do not know why FIBLAST PIII trials failed (wrong indication or stroke pts preconditions), but I do know that bFGF is important molecule and it will find its way to market.

Not only that FIBLAST is not at all valued in stock price, it hang on and have negative effect at this point. And it may have until SCIO clearly and loudly stated about FIBLAST: where are they, what they are doing and what are their plan for future (IMO). Regardless of the EU stroke trial outcome.

Natrecor is clear cut to me and I think that SCIO/Buyer will expand drug indications with new trials.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News